Wednesday, July 8, 2026

pharma · Recurrent Pericarditis · Sjögren’s Disease · KNSA

Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals is a pharma organization headquartered in Lexington, USA. It trades on NYSE under ticker KNSA. Primary therapeutic focus areas include Recurrent Pericarditis, Sjögren’s Disease, Well-Controlled Re

100 Hayden Ave, Lexington, Massachusetts 02421, US HQ
2015 Founded
381 Employees
Public company Type
KNSA · NYSE Ticker
Company details
Status
Public
HQ
100 Hayden Ave, Lexington, Massachusetts 02421, US
Founded
2015
Employees
381
Programs
14
Drugs
7
Patents
9
Clinical program

KPL-404

Phase 1 · small molecule · Healthy Volunteers

KPL-404 for Healthy Volunteers is a Phase 1 program (small_molecule) at Kiniksa Pharmaceuticals International, plc with 1 ClinicalTrials.gov record(s).

Internal code KPL-404-C101

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Kiniksa Pharmaceuticals International, plc
Phase
Phase 1
Modality
small_molecule
Indication
Healthy Volunteers
Status
completed
Trials
1

Clinical trials